Atlas Trials

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

Clinical trial NCT04484337 · COMPLETED

Trial details

NCT number
NCT04484337
Sponsor
ViiV Healthcare
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
HIV Infections
Start date
2020-07-31
Primary completion
2023-05-05
Enrollment
138

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.